Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study

• Autor(a) principal: Claro, Joaquim de Almeida [UNIFESP]
• Data de Publicação: 2001
• Outros Autores: Aboim, José Elêrton de [UNIFESP], Maríngolo, Marcelo [UNIFESP], Andrade, Enrico [UNIFESP], Aguiar, Wilson [UNIFESP], Nogueira, Marcos [UNIFESP], Nardozza Júnior, Archimedes [UNIFESP], Srougi, Miguel [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: https://dx.doi.org/10.1590/S1516-31802001000400004; https://repositorio.unifesp.br/handle/11600/1196
• topic: Prostate cancer; Erectile dysfunction; Self-injection therapy; Radical prostatectomy; Câncer da próstata; Disfunção erétil; Auto-injeção intracavernosa; Prostatectomia radical

CONTEXT: Despite the recent improvements in performing radical retropubic prostatectomy that have led to a considerable decrease in the complication rate, erectile dysfunction still represents a major problem. Moreover, less invasive treatment options that are emerging for erectile dysfunction have not shown satisfactory results in managing these patients. OBJECTIVE: To study the efficacy and side effects of self-injection therapy in the treatment of men who had become impotent after undergoing radical prostatectomy due to prostate cancer, over a study period of 96 months. DESIGN: Observational study. SETTING: University Referral Center. PARTICIPANTS: 168 patients with erectile dysfunction, aged 43 to 78 years old, who underwent radical retropubic prostatectomy due to localized prostate cancer. PROCEDURES: The patients were treated with self-injection therapy using papaverine, phentolamine and prostaglandin E1, at home. RESULTS: This study showed an acceptable 94.6% success rate, with no life-threatening complications. In addition to this, our series presented a 13.1% cure rate with this therapy. CONCLUSION: Self-injection therapy with papaverine, phentolamine and prostaglandin E1 is effective and safe in the treatment of erectile dysfunction after radical prostatectomy.